Symbols

APVO

Aptevo Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 1

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About APVO

Aptevo Therapeutics Inc.

A biotechnology company developing novel immunotherapies for cancer and autoimmune diseases

Industry

Biological Technology

Established Date

Listing Date

08/01/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.AptevoTherapeutics.com

Security Type

Common stock

Office address

2401 4th Avenue Suite 1050 Seattle Washington 98121

Business

Introduction

Aptevo Therapeutics Inc., was incorporated in Delaware in February 2016. The company is a clinical-stage R&D biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. The company has developed two multifunctional platform technologies for the rational design of precision immunomodulatory drugs.

Company Financials

EPS

APVO has released its 2025 Q2 earnings. EPS was reported at -8.4, versus the expected -0.25, missing expectations. The chart below visualizes how APVO has performed over recent quarters, highlighting trends in earnings surprises.